Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.84 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | PGR | P06401 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | RXRA | P19793 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.84 |
| ▸ | CCKAR | P32238 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.84 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL1786786 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL5056806 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL29380299 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL31002987 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL1147655 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL6251405 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41503 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41502 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41663 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL1147661 | 0.99 | CYP2C9 (0.98) | CYP2C9KDM4EALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5246844-A | — | — | None | — | — | JP | disclosed |
| US-20240139205-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | UNIVERSITE DE LAUSANNE (CH) | 2024-05-02 | — | — | US | disclosed |
| US-20220184058-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AORTIC ANEURYSM | NATIONAL UNIVERSITY CORPORATION HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) | 2022-06-16 | — | — | US | disclosed |
| EP-3939656-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AORTIC ANEURYSM | National University Corporation Hamamatsu University School of Medicine (JP) | 2022-01-19 | — | — | EP | disclosed |
| US-20210299118-A1 | Coordinated Metabolic Reprogramming in Response to Productive Viral Infections | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2021-09-30 | — | — | US | disclosed |
| US-20210290598-A1 | MEDICAMENT USEFUL FOR CARDIOVASCULAR DISEASE | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2021-09-23 | — | — | US | disclosed |
| US-11083725-B2 | Coordinated metabolic reprogramming in response to productive viral infections | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3791874-A1 | MEDICATION USEFUL FOR CARDIOVASCULAR DISEASES | National University Corporation Okayama University (JP) | 2021-03-17 | — | — | EP | disclosed |
| EP-2543729-B1 | MODEL ANIMAL FOR PREGNANCY-INDUCED HYPERTENSION SYNDROME, AND TREATMENT METHOD THEREFOR | OKABE MASARU (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-20170304293-A1 | COORDINATED METABOLIC REPROGRAMMING IN RESPONSE TO PRODUCTIVE VIRAL INFECTIONS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2003086495-A1 | MEDICAL PROSTHETIC DEVICES HAVING IMPROVED BIOCOMPATIBILITY | ASTRA TECH AB (SE) | 2003-10-23 | — | — | WO | disclosed |
| US-20030166946-A1 | Process for the preparation of indole derivatives and intermediates of the process | CIBA SPECIALTY CHEMICALS CORP. | 2003-09-04 | — | — | US | disclosed |
| EP-1339437-A1 | MEDICAL PROSTHETIC DEVICES AND IMPLANTS HAVING IMPROVED BIOCOMPATIBILITY | Astra Tech AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003018555-A1 | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES | CIBA SPECIALITY CHEMICALS HOLDING INC. (CH) | 2003-03-06 | — | — | WO | disclosed |
| EP-1284964-A1 | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES AND INTERMEDIATES OF THE PROCESS | Ciba SC Holding AG (CH) | 2003-02-26 | — | — | EP | disclosed |
| US-20020111694-A1 | Medical prosthetic devices and implants having improved biocompatibility | BIOTI AS (NO) | 2002-08-15 | — | — | US | disclosed |
| WO-2002045764-A1 | MEDICAL PROSTHETIC DEVICES AND IMPLANTS HAVING IMPROVED BIOCOMPATIBILITY | ASTRA TECH AB (SE) | 2002-06-13 | — | — | WO | disclosed |
| WO-2001092223-A1 | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES AND INTERMEDIATES OF THE PROCESS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-12-06 | — | — | WO | disclosed |
| JP-H05246844-A | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING HMG-COA REDUCTASE INHIBITORY COMPOUND | SANDOZ AG | 1993-09-24 | — | — | JP | disclosed |
| US-4870199-A | FROM 3-HYDROXY-4-TRIPHENYLMETHOXYBUTANOIC ACID | SANDOZ PHARM. CORP. (US) | 1989-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166946-A1 | Process for the preparation of indole derivatives and intermediates of the process | TPH1, IDO1, TDO2 | HMGCR 606/4885CYP2C9 116/4885KDM4E 884/4885 |
| US-20240139205-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | CYFIP1, GABARAPL1, GABRR1 | HMGCR 2165/4885CYP2C9 4165/4885KDM4E 3337/4885 |
| US-20210299118-A1 | Coordinated Metabolic Reprogramming in Response to Productive Viral Infections | MAVS, ATF4, PC | HMGCR 1824/4885CYP2C9 4672/4885KDM4E 1438/4885 |
| US-20170304293-A1 | COORDINATED METABOLIC REPROGRAMMING IN RESPONSE TO PRODUCTIVE VIRAL INFECTIONS | MAVS, ATF4, PC | HMGCR 1824/4885CYP2C9 4672/4885KDM4E 1438/4885 |
| US-11083725-B2 | Coordinated metabolic reprogramming in response to productive viral infections | MAVS, ATF4, PC | HMGCR 1824/4885CYP2C9 4672/4885KDM4E 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.